Sign inJoin waitlistJoin the waitlist

Christopher Logothetis

Professor · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
1977–1979
John H. Stroger Jr. Hospital of Cook County
1974–1977
Doctor of Medicine
1970–1974

Research

Abiraterone and increased survival in metastatic prostate cancer
New England Journal of Medicine · 2011 · 3,621 citations
Abiraterone in metastatic prostate cancer without previous chemotherapy
New England Journal of Medicine · 2013 · 2,325 citations
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Journal of Clinical Oncology · 2016 · 1,422 citations

Patricia Troncoso
89 papers
EE
Eleni Efstathiou
63 papers
Paul Corn
57 papers
Ana Aparicio
51 papers
JK
Jeri Kim
50 papers · 1 as a fellow
Shi-Ming Tu
44 papers · 1 as a fellow
RA
Robert Amato
41 papers
Louis Pisters
33 papers
Curtis Pettaway
31 papers
Lance Pagliaro
30 papers
John Araujo
28 papers
RM
Randall Millikan
28 papers

Grants

The University of Texas MD Anderson Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $146.9K · University of Tx Md Anderson Can Ctr
1996–2026
Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE
National Cancer Institute · P50
Contact PI · $23.4M · University of Tx Md Anderson Can Ctr
2009–2023
University of Texas SPORE in Prostate Cancer
National Cancer Institute · P50
Contact PI · $13.6M · University of Tx Md Anderson Can Ctr
2001–2007

Clinical trials

Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
Principal investigator · Recruiting
M.D. Anderson Cancer Center
2023–2029
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2020–2027
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2017–2021
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2013–2017